The study focuses on the complex dynamics of treating HER2-negative, HR-positive metastatic breast cancer with CDK46 inhibitors (CDK46i), emphasising exploring resistance patterns! The urgency for refined treatment strategies for metastatic breast cancer, marked by significant relapse rates, underscores the significance of the project. CDK46 inhibitors have emerged as a crucial first-line treatment for HR+/HER2 − metastatic breast cancer.

Our research utilises real-world data and artificial intelligence, particularly knowledge graphs, to thoroughly analyse CDK46i resistance factors. The primary objective is to assess subsequent treatment patterns and outcomes in metastatic breast cancer following first-line (1L) CDK46i treatment. Current knowledge gaps, especially concerning CDK46i, provide a compelling context, and the research employs cutting-edge methodologies to analyse Real World Data, extending insights beyond traditional clinical settings.

As an intern, you will contribute to a multidimensional approach to identify areas for improvement and guide targeted interventions to enhance patient outcomes. A vital aspect of this internship involves active participation in developing an R package, a practical tool streamlining knowledge graph creation. Initially tailored for CDK46i-treated metastatic breast cancer patients, this tool is designed to exceed its original purpose, providing a versatile solution for similar challenges across other oncology treatment medical settings.

Your role will include contributing to knowledge graph creation, unravelling patterns in patient journeys post-CDK46i resistance, and shedding light on the impacts of different treatment approaches on cancer outcomes. Integrating advanced analytical tools will be pivotal in transforming therapeutic strategies for HR+/HER2- metastatic breast cancer. This internship offers a unique opportunity to contribute significantly to the ongoing discourse in oncological research, and improved outcomes in the challenging realm of metastatic breast cancer treatment.

What are we looking for?

At AstraZeneca, we put patients first and strive to meet their unmet needs worldwide. We’re deeply committed to our strategy of being a great place to work. For us, that includes fostering an environment where everyone can be among inclusive, supportive individuals with curious minds.

A company that genuinely follows the science and values individuals at all levels, you’ll be backed and encouraged to speak up, ask questions, and share ideas to push the boundaries of science and continuously learn and explore.

Our purpose is bold and so is our approach. Becoming a more agile and innovative company means building a dynamic, inspiring culture where we celebrate entrepreneurial thinking and act with a sense of urgency. We are courageous, taking risks and learning from both success and failure. We are curious, creative, and open to new ideas and ways of working. Above all, we are passionate about science and driven to always put patients first. When you join us, you will be part of a great place to work; in an environment that energizes and empowers each of us to achieve our goal to develop and deliver medicines.

Date Posted

13-Feb-2024

Closing Date

05-Mar-2024Our mission is to build an inclusive and equitable environment. We want people to feel they belong at AstraZeneca and Alexion, starting with our recruitment process. We welcome and consider applications from all qualified candidates, regardless of characteristics. We offer reasonable adjustments/accommodations to help all candidates to perform at their best. If you have a need for any adjustments/accommodations, please complete the section in the application form.